Phase 2 Trial Open Enrollment for SPG302, First Synaptic Regenerative Approach to Treat Schizophrenia

6 Likes
1 Like

My doubt is in which part of the brain generates this supposed ‘‘repair’’. I don’t want to be pessimistic, but I don’t think it works in all cases of schizophrenia. The disease is very heterogeneous.

2 Likes

Probably take years to be approved. I’m sure cobenfy is a good antipsychotic, but seems to have more toxicity than some things. This new one sounds promising to me.

3 Likes

I know a guy who claims he’s on spg302. For him it had a pretty robust effect on his positives but didn’t affect his negatives.

1 Like